A sensitive flow cytometric assay has been developed using a monoclonal antibody, Myc 
Oncogenes are highly conserved regions of the normal genome and over 25 have been identified and many have also been cloned and sequenced (Bishop, 1984; Hamlyn & Sikora, 1983) . Changes in either the coding or control regions of these genes have been implicated in the development of cancer (Cooper & Lane, 1984; Krontiris, 1983) . Several molecular mechanisms resulting in the increased production of normal oncogene products or the development of aberrant proteins which subvert the normal growth control processes have now been uncovered (Der & Cooper, 1983; Stewart et al., 1984) . These include gene amplification, translocation, mutation, promotor insertion and rearrangement.
Such changes have been documented in fresh tumour biopsies from patients as well as cultured cell lines. (Rothberg et al., 1984; Favera et al., 1982) . The N-myc gene has been found to be amplified up to 100-fold in both neuroblastoma (Schwab et al., 1983) and retinoblastoma (Lee et al., 1984) using DNA hybridization techniques. In one patient with chronic myelocytic leukaemia, the c-myc sequence was amplified 16-fold and rearranged within the genome during episodes of transformation (McCarthy et al., 1984) . Amplification of this gene has been reported in cell lines derived from a very poor prognosis group of patients with small cell lung cancer (Little et al., 1983 ). K-ras and H-ras mRNA have been found elevated in colonic carcinoma, colonic polyps (Spandidos & Kerr, 1984) and breast cancer (Spandidos & Agnantis, 1984) . The structure and function of the oncogene protein products are now under active investigation. Those of c-sis and v-erb-B respectively code for a subunit of platelet derived growth factor, PDGF (Waterfield et al., 1983 ) and the internal domain of the epidermal growth factor receptor (Downward et al., 1984) .
Considerable interest has surrounded the ras and myc genes as marked variation has been found in the quantity of their transcripts in clinical biopsies at the RNA level (Slamon et al., 1984) . The c-myc gene product is a 62,000mol.w protein (p62UmYc) which may be involved in the transition from a quiescent to an actively dividing state. The level of c-myc mRNA increases as cells are stimulated into division (Kelly et al., 1983; Rabbitts et al., 1985; Makino et al., 1984; Thompson et al., 1985; Greenberg & Ziff, 1984) . Both mRNA transcripts and the protein itself have unusually short half-lives of 20 to 30min (Rabbitts et al., 1985; Hann et al., 1985) , a prerequisite for their putative cell proliferation control function. However, when cells have entered the cell cycle and protein level remains constant in G1, S and G2 (Hann et al., 1985; Rabbitts et al., 1985) . Furthermore, the protein binds to the nucleus, one of the likely sites for proliferation control (Evan & Hancock, 1985) . DNA . One of these antibodies (Myc-16E10) has been used to localize p62cmYc in formalin fixed histological sections from patients with testicular cancer . In this report we show that flow cytometric quantitation of p62c.mYc using Myc 1-6E10 in nuclei extracted from paraffin embedded testicular cancer biopsies can give prognostic information.
Materials and methods
Production of the anti-p-62CrnYc antibody Full details for the production and characterisation of the antibody are given elsewhere . Briefly, the DNA base sequence of the cloned gene was used to determine the amino acid structure of the protein. Synthetic peptides were then constructed to regions predicted to be hydrophillic and hence likely to be exposed on the surface of the complete molecule. Mice were immunised with the peptides to produce a number of monoclonal antibodies (MCAs) which immunoprecipitate a 62,000 dalton protein identifiable with the c-myc product. . One of these antibodies, Myc 1-6E10 raised to the 18 amino acid sequence from residues 173-188 (D-peptide), has been demonstrated to detect p62c-mYc in nuclei extracted from archival material .
35 pm nylon mesh to remove debris and clumps, centrifuged at 200g and resuspended in PBS, pH 7.4 at a concentration of 106 nuclei ml-1.
Aliquots of 1.0ml of the nuclear suspension were then placed into 1.5 ml tubes and spun down in an Eppendorf centrifuge. The supernatants were carefully removed and the nuclear pellets were resuspended in dilutions of Myc 1-6E10. A fluorescein labelled rabbit and anti-mouse immunoglobulin was added to probe the Myc 1-6E10 and the nuclei were counterstained with propidium iodide (PI) to assess DNA content .
The nuclei were analysed in the Cambridge MRC custom built flow cytometer (Watson, 1980 (Watson, , 1981 with a high efficiency light collection flow chamber (Watson, 1985) . The Innova-90 argon laser (Coherent, Palo Alto, CA) was turned to the 488 nm line which simultaneously excites red (DNA) and green (oncoprotein) fluorescence from individual nuclei. The data were stored on computer disc and following collection were recalled for display and analysis. Figure 2 shows an example of a data set from one patient with teratoma where a well pronounced aneuploid Patients A total of 38 patients attending Addenbrooke's Hospital with testicular cancer between the years 1967 to 1982 were included in this study. The only criteria of entry were a minimum follow up of 3 years from diagnosis and that sufficient material could be obtained from the stored biopsy of the primary lesion to perform the assay.
Extraction of nuclei, staining andflow cytometry The full technical details of our method have been published , but for convenience, the methodology is summarised in Figure 1 . The paraffin wax embedded biopsies were obtained from the Department of Pathology and care was taken, where possible, to check that the 20 pm sections used for analysis contained a majority of tumour tissue. This was effected by cutting alternate 4pm and 20 pm sections and examining the former histologically. Sufficient biopsy material was available from 33 of the 38 patients to perform this check and the vast majority of each section analysed was composed of tumour. This is consistent with the clinical behaviour of these lesions which tend to have infiltrated the majority of the testicular tissue at diagnosis. Isolated nuclei were extracted by pepsin digestion after dewaxing and xylene and rehydration. Our procedure is a modified version of the method described by Headley et al., (1983 The median fluorescence values associated with the diploid peak in seminoma and the aneuploid peak from a teratoma are shown for unblocked Myc 1-6E10 and after addition of the D-peptide (used as the immunogen) and the G-peptide (corresponding to the carboxy terminus of p62c-mYc) prior to the assay. Binding was blocked completely by the D-peptide but the G-peptide caused only a 14% and 11% signal decrease in seminoma and teratoma respectively.
An overall summary of p62c-mYc quantitation in testicular cancer versus clinical outcome is given in Figure 3 . All assays were performed blind and the median of the p62c-mYc fluorescence distribution associated with the diploid peak or the aneuploid component when present (3 patients) was calculated for each sample. The patients were then divided into two groups, those who were alive and well with no recurrence at 3 years after diagnosis and those who developed recurrence within this interval. were statistically different for all comparisons at P< 0.05 (see legend Figure 4 ). Nine patients with MTU and 1 patient with MTI died or developed recurrent disease within three years of diagnosis, the remaining 12 patients have remained alive and well with no recurrence for at least 3 years. When the MTU and MTI categories were combined we found the mean p62c-myc levels in the good and bad prognosis groups were 288 + 157 and 155 + 77 respectively ( Figure 5 ). t-test for comparison of means was 1.78 with 20 degrees of freedom, P<0.05.
There was no correlation between p62c-mYc level and the age of the patient, stage of disease, or serum levels of human chorionic gonadotrophin. The pre-treatment alpha foetoprotein levels were compared with p62C-myc and there was no correlation in MTU or MTI but a good correlation with tumours showing yolk sac differentiation.
Only 3 patients exhibited an aneuploid component on the DNA histogram. All were teratomas but the numbers are too small to make any useful observations on the prognostic significance of aneuploidy in this group of patients. However, these data sets gave some indication of p62cmYc levels in normal tissue assuming that the diploid components were indeed normal. The diploid peak in Figure 2 had a median p62c-myc level of 132 after subtracting the corresponding fluorescence control value. In the remaining two patients the diploid component comprised 10% and 30% of cells in the sample. These proportions correlated with the subjective assessment of normal cell content in the 4 m histological sections. The p62c-mYc levels in these diploid peaks were 68 and 110 respectively. One further patient, not included in this study, showed haploid, diploid and aneuploid components. This clearly was an 'oddball' from the DNA histogram and was later found to be an interstitial cell tumour. Both the haploid and diploid peaks had low p62c-mYc fluorescence, 50 and 90 respectively.
Discussion
We believe this to be the first report of an oncogene product quantitation in archival biopsies which has been correlated with morphology and clinical prognosis. Significant differences were found for all comparisons between seminoma and the three histological categories of teratoma. The p62C-mYc level increased with increasing differentiation in teratoma, and the good prognosis patients had significantly higher levels than the bad prognosis group. Presumed normal elements in biopsies containing aneuploid components had low p62c-mYc fluorescence with a mean of 90. This corresponds to the lowest end of the range found in MTU (Figure 3 ). Completely normal control testicular tissue within the age group 15 to 55 years spanning the ages of patients in this study was, comfortingly, impossible to find in our pathology archives. Orchidectomy specimens from patients with prostatic cancer were plentiful but the majority of these patients were over 65 and had been treated with oestrogens. Histologically these specimens were atrophic and totally unsuitable as controls for the patients reported here. The findings in teratoma were completely contrary to our initial expectation as oncogene amplification or increased mRNA transcripts have been found in a number of malignancies (Schwab et al., 1983; Lee et al., 1984; McCarthy et al., 1984; Little et al., 1983; Spandidos & Kerr, 1984; Spandidos & Agnantis, 1984) . However, an increase in either the gene or mRNA copy number (or both), which should give rise to an increased protein production rate, need not necessarily be reflected in a marked increase in the total protein content for two main reasons. Firstly, inappropriately increased message may result in rate limitation at the protein synthesis level. Secondly, an increase in protein degradation may offset an increased production rate. The latter is most likely to occur with a protein which has a short half-life and clearly, this is a distinct possibility for p62c-mYc with a half-life of 20-30min in rapidly cycling and stimulated cells (Rabbitts et al., 1985; Greenberg & Ziff, 1984) . Hence, the lower absolute levels in undifferentiated teratomas, compared with the better differentiated tumours, may reflect an increased protein turnover and an increased cell production rate in the former. A further possibility is that post transcriptional protein modification in the more malignant tumours may give rise to an alteration or partial occlusion of the epitope recognised by Myc 1-6E10. However, these possibilities will not be resolved with archival data and will probably require the function of the protein to be elucidated.
In spite of our lack of knowledge of the protein's function these results demonstrate that there is considerable potential clinical significance in quantitating oncogene products in wax embedded stored biopsy material. The clinical outcome will already be known in most cases and consequently prognostic correlates can be discovered rapidly. Our results using Myc 1-6E10 with immunoperoxidase staining in teratoma show good agreement between the quantitative flow cytometric analysis and the subjective results of immunohistology .
One of our objectives in these studies was to define quantitative biochemical differences between good and bad prognosis groups in which the morphology is very similar or identical. This would be of direct relevance to patient care by being able to identify those poor risk patients for whom new therapeutic schedules would have to be found. These studies have gone some way to achieving this by demonstrating a difference between the mean p62c-mYc levels in the good and bad prognosis l teratoma groups. Although we have found significant differences between the prognostic subsets in teratoma it would not be possible to predict reliably into which group an individual would fall from our current data (see Figure 5) . However, c-myc is one of many oncogenes and the measurement of combinations of these gene products simultaneously may provide more accurate prognostic data. Those of the p53, c-fos and c-myb genes are also nuclear binding and should, therefore, be amenable to analysis using this method when suitable MCAs become available.
